Arvinas (NASDAQ:ARVN) Shareholders Have Endured a 74% Loss From Investing in the Stock Three Years Ago
Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares
Cantor Fitzgerald Reiterates Overweight on Arvinas
Arvinas Analyst Ratings
Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth
Arvinas to Participate in Upcoming Investor Conferences
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
Barclays analyst Peter Lawson maintains $Arvinas(ARVN.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 44.4% and a total
Arvinas Holding Company (ARVN) Receives a Buy From Barclays
Express News | Arvinas Inc - Agreed to Pay a One-Time Cash Termination Fee of $41.5 Mln
Express News | Arvinas Inc - on August 15 Unit Entered Into a Lease Termination Agreement With 101 College Street, LLC
Ping An Securities: AR inhibitors promote the optimization of drug use structure, while new types of therapy such as nuclear medicine continue to emerge.
Full-course management is increasingly valued in the diagnosis and treatment of prostate cancer, with the aim of extending patients' survival benefits.
Arvinas Holding Company (ARVN) Receives a Buy From Truist Financial
Express News | Arvinas Inc : Citigroup Cuts Target Price to $30 From $38
Analysts Conflicted on These Healthcare Names: BioLife Solutions (BLFS), Arvinas Holding Company (ARVN) and Natera (NTRA)
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Cuts Target Price to $48
Morgan Stanley analyst Terence Flynn maintains $Arvinas(ARVN.US)$ with a hold rating, and adjusts the target price from $51 to $48.According to TipRanks data, the analyst has a success rate of 63.1%
Brokers Are Upgrading Their Views On Arvinas, Inc. (NASDAQ:ARVN) With These New Forecasts
Stifel Maintains Arvinas(ARVN.US) With Buy Rating, Cuts Target Price to $63
Stifel analyst Bradley Canino maintains $Arvinas(ARVN.US)$ with a buy rating, and adjusts the target price from $68 to $63.According to TipRanks data, the analyst has a success rate of 52.4% and a
Arvinas Holding Company (ARVN) Receives a Buy From Stifel Nicolaus
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Truist Financial Maintains Arvinas(ARVN.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Arvinas(ARVN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 54.8% and a total average return of 7.7%